Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel P. Cahill, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Cahill and Jorg Dietrich.
Connection Strength

1.065
  1. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist. 2019 03; 24(3):402-413.
    View in: PubMed
    Score: 0.193
  2. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
    View in: PubMed
    Score: 0.160
  3. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 Mar 14; 13(1):1325.
    View in: PubMed
    Score: 0.062
  4. In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging. J Magn Reson Imaging. 2021 Dec 27.
    View in: PubMed
    Score: 0.061
  5. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun. 2021 10 12; 12(1):5954.
    View in: PubMed
    Score: 0.060
  6. Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B0 -shim array coils at 3?T. NMR Biomed. 2022 01; 35(1):e4621.
    View in: PubMed
    Score: 0.060
  7. A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood. 2021 08 05; 138(5):382-386.
    View in: PubMed
    Score: 0.059
  8. An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 T. Sci Rep. 2020 09 14; 10(1):15029.
    View in: PubMed
    Score: 0.056
  9. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.055
  10. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.055
  11. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.055
  12. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology. 2020 03; 294(3):589-597.
    View in: PubMed
    Score: 0.053
  13. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019 02 12; 3(3):375-383.
    View in: PubMed
    Score: 0.050
  14. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.047
  15. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.